The Treatment of Tuberculosis

Area of Science:

• Infectious Diseases
• Pharmacology
• Global Health

Background:

• Tuberculosis (TB) is a major global infectious cause of death, exacerbated by poverty.
• TB presents clinically as latent or active disease, requiring distinct treatment approaches.
• Drug resistance in TB is a growing public health concern.

Purpose of the Study:

• To review current understanding of TB drug activities and challenges in treatment.
• To explore advancements in treating drug-susceptible and drug-resistant TB.
• To highlight the role of pharmacokinetics and pharmacodynamics in optimizing TB therapy.

Main Methods:

• Review of TB drug properties, including early bactericidal activity (EBA) and sterilizing activity.
• Discussion of first-line and alternative drug regimens for TB.
• Examination of challenges like drug penetration and adverse drug reactions.
• Utilizing hollow fiber infection models (HFIM) and animal models for PK/PD studies.

Main Results:

• Isoniazid shows strong EBA, while rifampin excels at sterilizing activity.
• New and repurposed drugs are crucial for treating drug-resistant TB.
• Pharmacodynamic principles (AUC/MIC) guide drug selection and regimen design.
• PK/PD models facilitate the development of potent, shorter TB treatment regimens.

Conclusions:

• Optimizing drug exposure through therapeutic drug monitoring and dose individualization is key to effective TB treatment.
• Advanced PK/PD modeling can accelerate the development of optimal regimens for even extensively drug-resistant TB.
• Addressing challenges in drug penetration and managing adverse effects remains critical for successful TB eradication.